Diplomat Pharmacy (NYSE:DPLO) Price Target Raised to $5.50 at Wells Fargo & Co

Share on StockTwits

Diplomat Pharmacy (NYSE:DPLO) had its target price raised by Wells Fargo & Co from $5.00 to $5.50 in a report issued on Tuesday morning, BenzingaRatingsTable reports. The brokerage currently has a market perform rating on the stock.

A number of other analysts have also recently commented on DPLO. Guggenheim began coverage on Diplomat Pharmacy in a research report on Wednesday, April 17th. They set a neutral rating and a $6.00 price objective for the company. Barclays set a $7.00 price objective on Diplomat Pharmacy and gave the company a buy rating in a research report on Friday, August 9th. Credit Suisse Group reduced their price objective on Diplomat Pharmacy from $8.00 to $6.00 and set a neutral rating for the company in a research report on Monday, April 29th. Zacks Investment Research cut Diplomat Pharmacy from a buy rating to a hold rating in a research report on Tuesday, July 16th. Finally, ValuEngine upgraded Diplomat Pharmacy from a buy rating to a strong-buy rating in a research report on Thursday, August 1st. Two analysts have rated the stock with a sell rating, ten have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Diplomat Pharmacy currently has a consensus rating of Hold and an average price target of $9.85.

Shares of NYSE:DPLO opened at $5.39 on Tuesday. The company has a market capitalization of $427.36 million, a P/E ratio of 26.95 and a beta of 1.06. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.66 and a current ratio of 1.00. Diplomat Pharmacy has a 1 year low of $4.17 and a 1 year high of $21.48. The firm’s fifty day simple moving average is $5.59.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.23 billion. Diplomat Pharmacy had a negative net margin of 8.93% and a negative return on equity of 3.54%. The firm’s revenue was down 9.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.05) EPS. On average, sell-side analysts expect that Diplomat Pharmacy will post -2.62 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Public Employees Retirement System of Ohio increased its position in Diplomat Pharmacy by 8.0% in the second quarter. Public Employees Retirement System of Ohio now owns 54,502 shares of the company’s stock worth $332,000 after buying an additional 4,047 shares in the last quarter. Bank of Montreal Can increased its position in Diplomat Pharmacy by 138.4% in the second quarter. Bank of Montreal Can now owns 11,444 shares of the company’s stock worth $70,000 after buying an additional 6,644 shares in the last quarter. KBC Group NV purchased a new stake in Diplomat Pharmacy in the second quarter worth about $46,000. BNP Paribas Arbitrage SA increased its position in Diplomat Pharmacy by 446.9% in the first quarter. BNP Paribas Arbitrage SA now owns 13,104 shares of the company’s stock worth $76,000 after buying an additional 10,708 shares in the last quarter. Finally, Quantamental Technologies LLC purchased a new stake in Diplomat Pharmacy in the first quarter worth about $63,000. Institutional investors and hedge funds own 87.62% of the company’s stock.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Further Reading: Investing strategies using the yield curve

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

EJF Capital LLC Lowers Stake in Sandy Spring Bancorp Inc.
EJF Capital LLC Lowers Stake in Sandy Spring Bancorp Inc.
EJF Capital LLC Buys New Position in Radian Group Inc
EJF Capital LLC Buys New Position in Radian Group Inc
EJF Capital LLC Has $7.26 Million Position in Rhinebeck Bancorp Inc
EJF Capital LLC Has $7.26 Million Position in Rhinebeck Bancorp Inc
EJF Capital LLC Buys Shares of 402,288 Mainstreet Bank Common Stock
EJF Capital LLC Buys Shares of 402,288 Mainstreet Bank Common Stock
EJF Capital LLC Grows Stock Position in First Savings Financial Group Inc
EJF Capital LLC Grows Stock Position in First Savings Financial Group Inc
SB Financial Group Inc  Shares Bought by EJF Capital LLC
SB Financial Group Inc Shares Bought by EJF Capital LLC


© 2006-2019 Ticker Report